Comparative Pharmacology
Head-to-head clinical analysis: LUZU versus NIZORAL ANTI DANDRUFF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUZU versus NIZORAL ANTI DANDRUFF.
LUZU vs NIZORAL ANTI-DANDRUFF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Ketoconazole, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase (CYP51), preventing the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes. This disrupts membrane integrity and function.
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
Apply to wet hair, lather, and leave on for 3-5 minutes before rinsing. Use twice weekly for 4 weeks, then as needed to control dandruff.
None Documented
None Documented
The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application.
Terminal elimination half-life is biphasic: initial 2 hours, terminal 8 hours (range 6-10 hours). After topical application, systemic absorption is minimal, resulting in an effective half-life of 72-96 hours in skin.
Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route.
Primarily fecal (57%) via biliary excretion as unchanged drug and metabolites; renal excretion accounts for approximately 13% (2-4% unchanged).
Category C
Category C
Topical Antifungal
Topical Antifungal